Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Apr;19(2):157-73.
doi: 10.1007/BF01073867.

The pharmacokinetics of aspirin in rats and the effect of buffer

Affiliations

The pharmacokinetics of aspirin in rats and the effect of buffer

C J Fu et al. J Pharmacokinet Biopharm. 1991 Apr.

Abstract

Aspirin (acetylsalicyclic acid) was administered to rats intravenously, orally, and intraintestinally at different doses or in different dosage forms. The distribution and elimination kinetics of aspirin in rats following intravenous administration were best described by a two-compartmental open system and were dose independent up to 15 mg/kg. The terminal elimination half-life following intravenous dosing (10 mg/kg) was 3.36 +/- 0.85 min (n = 15) with the clearance being 8.40 +/- 1.24 L/(kg.hr). Intravenous distribution and elimination kinetics of aspirin in rats were not influenced by an orally administered buffered solution with a buffer capacity of 0.933 mEq ANC (acid neutralizing capacity) per kg of body weight. However, this orally buffered solution did change the gastrointestinal absorption kinetics of aspirin in rats. The absolute bioavailable dose of aspirin was 56.6 +/- 10.4% (n = 6) following its administration in an unbuffered solution while it was only 31.8 +/- 8.0% (n = 6) following administration in the buffered solution. The corresponding values of the absolute bioavailable doses were 43.4 +/- 3.7% and 25.5 +/- 1.8% following intraintestinal administration. The lower systemic availability of aspirin in the presence of buffer is attributed to a greater fraction of the administered dose becoming available for absorption from the intestine where the extraction efficiency is higher than that in the stomach.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Pharm Sci. 1972 Mar;61(3):379-85 - PubMed
    1. J Pharmacol Exp Ther. 1958 May;123(1):81-8 - PubMed
    1. J Pharmacol Exp Ther. 1988 Jun;245(3):809-15 - PubMed
    1. Clin Pharmacol Ther. 1979 Aug;26(2):145-52 - PubMed
    1. J Pharm Sci. 1969 Jan;58(1):71-5 - PubMed